Kumamoto University Graduate School of Medical Science – Bioethics, Honjo 1-1-1, Kumamoto, Japan.
Bioethics. 2013 May;27(4):186-93. doi: 10.1111/j.1467-8519.2011.01943.x. Epub 2012 Feb 2.
A placebo is a substance or intervention believed to be inactive, but is administered by the healthcare professional as if it was an active medication. Unlike standard treatments, clinical use of placebo usually involves deception and is therefore ethically problematic. Our attitudes toward the clinical use of placebo, which inevitably includes deception or withholding information, have a tremendous effect on our practice regarding truth-telling and informed consent. A casual attitude towards it weakens the current practice based on shared decision-making and mutual trust between patients and healthcare professionals. Issues concerning the clinical use of placebo are thus intimately related to patient-provider relationships, the public's trust in medicine, and medical education. A review of recent survey studies suggests that the clinical use of placebo appears to be fairly well accepted among healthcare professionals and is common in clinical settings in various countries. However, we think that an ethical discussion is urgently needed because of its controversial nature. If judged to be ethically wrong, the practice should end. In the present paper, we discuss the ethicality of the clinical use of placebo with deception and argue against it, concluding that it is unethical and should be banned. We will show that most arguments in favor of the clinical use of placebo can be refuted and are therefore incorrect or weak. These arguments will be presented and examined individually. Finally, we will briefly consider issues relevant to the clinical use of placebo without deception.
安慰剂是一种被认为是无效的物质或干预措施,但由医疗保健专业人员给予,就好像它是一种有效的药物一样。与标准治疗不同,安慰剂的临床应用通常涉及欺骗,因此在伦理上存在问题。我们对安慰剂临床应用的态度,不可避免地包括欺骗或隐瞒信息,对我们关于说实话和知情同意的实践有巨大影响。对其持随意态度会削弱当前基于患者和医疗保健专业人员之间共同决策和相互信任的实践。因此,安慰剂临床应用的问题与医患关系、公众对医学的信任和医学教育密切相关。最近的调查研究综述表明,安慰剂的临床应用在医疗保健专业人员中似乎得到了相当好的接受,并且在不同国家的临床环境中也很常见。然而,我们认为由于其争议性质,迫切需要进行伦理讨论。如果判断为不道德,则应停止这种做法。在本文中,我们将讨论具有欺骗性的安慰剂临床应用的伦理问题并反对这种做法,得出的结论是它不道德,应该被禁止。我们将表明,支持安慰剂临床应用的大多数论点都可以被反驳,因此是不正确或薄弱的。这些论点将被单独提出并加以检验。最后,我们将简要考虑与无欺骗性安慰剂临床应用相关的问题。